Cancer Causes & Control

, Volume 28, Issue 11, pp 1265–1273 | Cite as

Prostate cancer clinical presentation, incidence, mortality and survival in Guadeloupe over the period 2008–2013 from a population-based cancer registry

  • J. DeloumeauxEmail author
  • B. Bhakkan
  • R. Eyraud
  • F. Braud
  • N. Manip M’Ebobisse
  • P. Blanchet
  • L. Brureau
Original paper



The Caribbean population of Guadeloupe has one of the highest incidence rates of prostate cancer worldwide. In 2008, a population-based cancer registry was set up for the monitoring of cancer incidence in the aftermath of the environmental pollution with chlordecone, a persistent organochlorine insecticide formerly used in banana plantations. We describe the clinical presentation, incidence, mortality and survival of prostate cancer for the period 2008–2013.


The Guadeloupe cancer registry has been routinely collecting all incident cases of cancer since 2008. We compared age-specific incidence rates between different populations, and calculated incidence and mortality rates standardized to the world population. Kaplan–Meier observed survival and estimated age-standardized net survival were calculated by category for age, PSA level, and Gleason score using the Pohar-Perme method.


Overall, 3,295 cases of prostate cancer were recorded. World-standardized incidence and mortality were respectively 184.1 [177.8–190.4] and 23.9 [21.9–25.7] per 100,000 person-years. At diagnosis, the mean age of patients was 68 ± 9.6 years old and 22% were aged over 75. Median PSA level was 8.9 [IQR: 6.0–16.0] and 13.6% of the patients had a Gleason ≥ 8. Five-year observed and net survivals were, respectively, 79.6% [77.9–81.2] and 90.7% [88.6–92.8].


The incidence of prostate cancer in Guadeloupe is among the highest in the world, along with those of the neighboring Caribbean countries and US African-Americans. We observed no decrease in incidence rates, and a decreasing but non-significant trend in mortality rates, which nonetheless remain higher than in high-income countries. Many Genome-Wide Association Studies are conducted to identify genetic markers involved in prostate cancer risk. In the Caribbean, complementary studies on both lifestyle and behavioral factors should highlight potential common risks among populations who share both genetic and environmental characteristics.


Prostate cancer Incidence Mortality Survival Guadeloupe Caribbean 



The cancer registry of Guadeloupe receives financial support from l’Institut National du Cancer (INCa) and Santé Publique France.


  1. 1.
    Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F (2012) International variation in prostate cancer incidence and mortality rates. Eur Urol 61(6):1079–1092. doi: 10.1016/j.eururo.2012.02.054 CrossRefPubMedGoogle Scholar
  2. 2.
    Ilic D, Neuberger MM, Djulbegovic M, Dahm P (2013) Screening for prostate cancer. Cochrane database of systematic reviews. BJU Int. doi: 10.1002/14651858.CD004720 Google Scholar
  3. 3.
    Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ (2002) Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 94(13):981–990CrossRefPubMedGoogle Scholar
  4. 4.
    Vickers AJ, Sjoberg DD, Ulmert D, Vertosick E, Roobol MJ, Thompson I, Heijnsdijk EA, De Koning H, Atoria-Swartz C, Scardino PT, Lilja H (2014) Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen. BMC Med 12:26. doi: 10.1186/1741-7015-12-26 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R (2014) Overdiagnosis and overtreatment of prostate cancer. Eur Urol 65(6):1046–1055. doi: 10.1016/j.eururo.2013.12.062 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2013) GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer. Accessed 21 Jan 2017Google Scholar
  7. 7.
    Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, Morrison H, Sonawane B, Shifflett T, Waters DJ, Timms B (2004) Human prostate cancer risk factors. Cancer 101:2371–2490. doi: 10.1002/cncr.20408 CrossRefPubMedGoogle Scholar
  8. 8.
    Hu WY, Shi GB, Hu DP, Nelles JL, Prins GS (2012) Actions of estrogens and endocrine disrupting chemicals on human prostate stem/progenitor cells and prostate cancer risk. Mol Cell Endocrinol 354(1–2):63–73. doi: 10.1016/j.mce.2011.08.032 CrossRefPubMedGoogle Scholar
  9. 9.
    Bergman Å, Heindel JJ, Jobling S, Kidd K, Zoeller TR (2013) State of the science of endocrine disrupting chemicals 2012, 2013 edn. United Nations Environment Programme and the World Health Organization.Google Scholar
  10. 10.
    Mallick S, Blanchet P, Multigner L (2005) Prostate cancer incidence in guadeloupe, a French Caribbean archipelago. Eur Urol 47(6):769–772. doi: 10.1016/j.eururo.2005.02.020 CrossRefPubMedGoogle Scholar
  11. 11.
    Cabidoche YM, Achard R, Cattan P, Clermont-Dauphin C, Massat F, Sansoulet J (2009) Long-term pollution by chlordecone of tropical volcanic soils in the French west indies: a simple leaching model accounts for current residue. Environ Pollut 157(5):1697–1705. doi: 10.1016/j.envpol.2008.12.015 CrossRefPubMedGoogle Scholar
  12. 12.
    Crabit A, Cattan P, Colin F, Voltz M (2016) Soil and river contamination patterns of chlordecone in a tropical volcanic catchment in the French West Indies (Guadeloupe). Environ Pollut 212:615–626. doi: 10.1016/j.envpol.2016.02.055 CrossRefPubMedGoogle Scholar
  13. 13.
    Dromard CR, Bodiguel X, Lemoine S, Bouchon-Navaro Y, Reynal L, Thouard E, Bouchon C (2016) Assessment of the contamination of marine fauna by chlordecone in Guadeloupe and Martinique (Lesser Antilles). Environ Sci Pollut Res 23(1):73–80. doi: 10.1007/s11356-015-4732-z CrossRefGoogle Scholar
  14. 14.
    Charlotte DR, Yolande BN, Cordonnier S, Claude B (2016) The invasive lionfish, Pterois volitans, used as a sentinel species to assess the organochlorine pollution by chlordecone in Guadeloupe (Lesser Antilles). Mar Pollut Bull. doi: 10.1016/j.marpolbul.2016.04.012 PubMedGoogle Scholar
  15. 15.
    Multigner L, Kadhel P, Rouget F, Blanchet P, Cordier S (2016) Chlordecone exposure and adverse effects in French West Indies populations. Environ Sci Pollut Res 23(1):3–8. doi: 10.1007/s11356-015-4621-5 CrossRefGoogle Scholar
  16. 16.
    Grosclaude P, Belot A, Daubisse Marliac L, Remontet L, Leone N, Bossard N, Velten M, Francim. R (2015) Prostate cancer incidence and mortality trends in France from 1980 to 2011. Prog Urol 25(9):536–542. doi: 10.1016/j.purol.2015.04.011 CrossRefPubMedGoogle Scholar
  17. 17.
    INSEE (2016) French population estimation from 1975 to 2015, by area, sex and age [Estimation de population au 1er janvier, par région, sexe et âge quinquennal]. Accessed May 2016
  18. 18.
    Doll R, Payne P (1966) Cancer incidence in five continents, vol 1. Union Internationale Contre le Cancer, GenevaCrossRefGoogle Scholar
  19. 19.
    Segi M (1960) Cancer mortality for selected sites in 24 countries (1950–57). Department of Public Health, Tohoku University of Medicine, SendaiGoogle Scholar
  20. 20.
  21. 21.
    Kim HJ, Fay P, Feuer EJ, Midthune DN (2000) Permutation tests for joinpoint regression with applications to cancer rates. Statistics in Medicine 19(3):335–351CrossRefPubMedGoogle Scholar
  22. 22.
    Kaplan EL, Meier P (1958) Nonparametric Estimation from Incomplete Observations. J Am Stat Assoc 53(282):457–481. doi: 10.1080/01621459.1958.10501452 CrossRefGoogle Scholar
  23. 23.
    Perme MP, Stare J, Esteve J (2012) On estimation in relative survival. Biometrics 68(1):113–120. doi: 10.1111/j.1541-0420.2011.01640.x CrossRefPubMedGoogle Scholar
  24. 24.
    Roche L, Danieli C, Belot A, Grosclaude P, Bouvier AM, Velten M, Iwaz J, Remontet L, Bossard N (2013) Cancer net survival on registry data: use of the new unbiased Pohar-Perme estimator and magnitude of the bias with the classical methods. Int J Cancer 132(10):2359–2369. doi: 10.1002/ijc.27830 CrossRefPubMedGoogle Scholar
  25. 25.
    Morgan TO, Jacobsen SJ, McCarthy WF, Jacobson DJ, McLeod DG, Moul JW (1996) Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 335(5):304–310. doi: 10.1056/NEJM199608013350502 CrossRefPubMedGoogle Scholar
  26. 26.
    Smith DS, Carvalhal GF, Mager DE, Bullock AD, Catalona WJ (1998) Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men. J Urol 160(5):1734–1738CrossRefPubMedGoogle Scholar
  27. 27.
    Telesca D, Etzioni R, Gulati R (2008) Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics 64(1):10–19. doi: 10.1111/j.1541-0420.2007.00825.x CrossRefPubMedGoogle Scholar
  28. 28.
    Multigner L, Ndong JR, Giusti A, Romana M, Delacroix-Maillard H, Cordier S, Jegou B, Thome JP, Blanchet P (2010) Chlordecone exposure and risk of prostate cancer. J Clin Oncol 28(21):3457–3462. doi: 10.1200/JCO.2009.27.2153 CrossRefPubMedGoogle Scholar
  29. 29.
    Emeville E, Broquere C, Brureau L, Ferdinand S, Blanchet P, Multigner L, Romana M (2014) Copy number variation of GSTT1 and GSTM1 and the risk of prostate cancer in a Caribbean population of African descent. PLoS ONE 9(9):e107275. doi: 10.1371/journal.pone.0107275 CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Lafontaine A, Hanikenne M, Boulangé-Lecomte C, Forget-Leray J, Thomé JP, Gismondi E (2016) Vitellogenin and vitellogenin receptor gene expression and 20-hydroxyecdysone concentration in Macrobrachium rosenbergii exposed to chlordecone. Environ Sci Pollut Res Int 23(20):20661–20671CrossRefPubMedGoogle Scholar
  31. 31.
    Brureau L, Moningo D, Emeville E, Ferdinand S, Punga A, Lufuma S, Blanchet P, Romana M, Multigner L (2016) Polymorphisms of estrogen metabolism-related genes and prostate cancer risk in two populations of African Ancestry. PLoS ONE 11(4):e0153609. doi: 10.1371/journal.pone.0153609 CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Kooiman GG, Martin FL, Williams JA, Grover PL, Phillips DH, Muir GH (2000) The influence of dietary and environmental factors on prostate cancer risk. Prostate Cancer Prostatic Dis 3(4):256–258. doi: 10.1038/sj.pcan.4500489 CrossRefPubMedGoogle Scholar
  33. 33.
    Bassett JK, Severi G, Baglietto L, MacInnis RJ, Hoang HN, Hopper JL, English DR, Giles GG (2012) Weight change and prostate cancer incidence and mortality. Int J Cancer 131(7):1711–1719. doi: 10.1002/ijc.27414 CrossRefPubMedGoogle Scholar
  34. 34.
    Prevention CfDCa (2009) Differences in prevalence of obesity among black, white, and Hispanic adults—United States, 2006–2008. MMWR Morb Mortal Wkly Rep 58 (27):740–744Google Scholar
  35. 35.
    Khan S, Cai J, Nielsen ME, Troester MA, Mohler JL, Fontham ET, Hendrix LH, Farnan L, Olshan AF, Bensen JT (2016) The association of diabetes and obesity with prostate cancer aggressiveness among Black Americans and White Americans in a population-based study. Cancer Causes Control 27(12):1475–1485. doi: 10.1007/s10552-016-0828-0 CrossRefPubMedGoogle Scholar
  36. 36.
    Park SY, Haiman CA, Cheng I, Park SL, Wilkens LR, Kolonel LN, Le Marchand L, Henderson BE (2015) Racial/ethnic differences in lifestyle-related factors and prostate cancer risk: the multiethnic cohort study. Cancer Causes Control 26(10):1507–1515. doi: 10.1007/s10552-015-0644-y CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Daigre JL, Atallah A, Boissin JL, Jean-Baptiste G, Kangambega P, Chevalier H, Balkau B, Smadja D, Inamo J (2012) The prevalence of overweight and obesity, and distribution of waist circumference, in adults and children in the French Overseas Territories: the PODIUM survey. Diabetes Metab 38(5):404–411. doi: 10.1016/j.diabet.2012.03.008 CrossRefPubMedGoogle Scholar
  38. 38.
    Gonzalez MC, Correia MITD, Heymsfield SB (2017) A requiem for BMI in the clinical setting. Curr Opin Clin Nutr Metab Care 20(5):314–321. doi: 10.1097/MCO.0000000000000395 CrossRefPubMedGoogle Scholar
  39. 39.
    Von Hafe P, Pina F, Pérez A, Tavares M, Barros H (2004) Visceral fat accumulation as a risk factor for prostate cancer. Obes Res 12(12):1930–1935. doi: 10.1038/oby.2004.242 CrossRefGoogle Scholar
  40. 40.
    Razzaghi H, Quesnel-Crooks S, Sherman R, Joseph R, Kohler B, Andall-Brereton G, Ivey MA, Edwards BK, Mery L, Gawryszewski V, Saraiya M (2016) Leading causes of cancer mortality—Caribbean Region, 2003–2013. Morb Mortal Wkly Rep 65(49):1395–1400. doi: 10.15585/mmwr.mm6549a3 CrossRefGoogle Scholar
  41. 41.
    Miller DC, Gelberg L, Kwan L, Stepanian S, Fink A, Andersen RM, Litwin MS (2008) Racial disparities in access to care for men in a public assistance program for prostate cancer. J Community Health 33(5):318–335. doi: 10.1007/s10900-008-9105-9 CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Walsh PC (2005) Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States. J Urol 174(4 Pt 1):1294–1295CrossRefPubMedGoogle Scholar
  43. 43.
    Robbins AS, Yin D, Parikh-Patel A (2007) Differences in prognostic factors and survival among White men and Black men with prostate cancer, California, 1995–2004. Am J Epidemiol 166(1):71–78. doi: 10.1093/aje/kwm052 CrossRefPubMedGoogle Scholar
  44. 44.
    Cancel-Tassin G, Romana M, Gaffory C, Blanchet P, Cussenot O, Multigner L (2015) Region 2 of 8q24 is associated with the risk of aggressive prostate cancer in Caribbean men of African descent from Guadeloupe (French West Indies). Asian J Androl 17(1):117–119. doi: 10.4103/1008-682X.135127 CrossRefPubMedGoogle Scholar
  45. 45.
    Okobia MN, Zmuda JM, Ferrell RE, Patrick AL, Bunker CH (2011) Chromosome 8q24 variants are associated with prostate cancer risk in a high risk population of African ancestry. Prostate 71(10):1054–1063. doi: 10.1002/pros.21320 CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A, Marcos-Gragera R, Stiller C, Azevedo e Silva G, Chen WQ, Ogunbiyi OJ, Rachet B, Soeberg MJ, You H, Matsuda T, Bielska-Lasota M, Storm H, Tucker TC, Coleman MP, Group CW (2015) Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 385(9972):977–1010. doi: 10.1016/S0140-6736(14)62038-9 CrossRefPubMedGoogle Scholar
  47. 47.
    Stroup AM, Cho H, Scoppa SM, Weir HK, Mariotto AB (2014) The impact of state-specific life tables on relative survival. J Natl Cancer Inst Monogr. doi: 10.1093/jncimonographs/lgu017 PubMedPubMedCentralGoogle Scholar
  48. 48.
    Howlader N, Ries LAG, Mariotto AB, Reichman ME, Ruhl J, Cronin KA (2010) Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst 102(20):1584–1598. doi: 10.1093/jnci/djq366 CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Cho H, Mariotto AB, Mann BS, Klabunde CN, Feuer EJ (2013) Assessing non-cancer-related health status of US cancer patients: other-cause survival and comorbidity prevalence. Am J Epidemiol 178(3):339–349. doi: 10.1093/aje/kws580 CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Eeles R, Goh C, Castro E, Bancroft E, Guy M, Olama AAA, Easton D, Kote-Jarai Z (2014) The genetic epidemiology of prostate cancer and its clinical implications. Nat Rev Urol 11(1):18–31. doi: 10.1038/nrurol.2013.266 CrossRefPubMedGoogle Scholar
  51. 51.
    Virlogeux V, Graff RE, Hoffmann TJ, Witte JS (2015) Replication and heritability of prostate cancer risk variants: Impact of population-specific factors. Cancer Epidemiol Biomarkers Prev 24(6):938–943. doi: 10.1158/1055-9965.EPI-14-1372 CrossRefPubMedGoogle Scholar
  52. 52.
    Odedina FT, Akinremi TO, Chinegwundoh F, Roberts R, Yu D, Reams RR, Freedman ML, Rivers B, Green BL, Kumar N (2009) Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa. Infect Agent Cancer 4(Suppl 1):S2. doi: 10.1186/1750-9378-4-S1-S2 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Registre général des cancers de GuadeloupeCentre Hospitalier Universitaire de Pointe-à-PitrePointe-à-PitreFrance
  2. 2.Service d’UrologieCentre Hospitalier Universitaire de Pointe-à-PitrePointe-à-PitreFrance
  3. 3.Clinique des Eaux-ClairesPointe-à-PitreFrance
  4. 4.Service d’Oncologie-RadiothérapieCentre Hospitalier Universitaire de Pointe-à-PitrePointe-à-PitreFrance
  5. 5.INSERM, U1085 - IRSETPointe-à-PitreFrance

Personalised recommendations